Advancing patient-centric QA – Dosimetry Check™ fully ported to RadCalc 7.2
The development and support of Dosimetry Check™ as a standalone software will no longer continue. Therefore, Dosimetry Check v5.8 and earlier has reached its end of life (EOL) as of 31 December, 2022.
Our customers and the market recognize Dosimetry Check™ as groundbreaking software, with many academic publications verifying its applicability and effectiveness in radiation therapy. With this in mind, we are pleased to announce that the advanced EPID dosimetry functionality for 3D dose reconstruction and verification is now fully available in RadCalc Version 7.2. The RadCalc team is excited to have successfully integrated the proven measurement-based 3D EPID dosimetric functionality for patient pre-treatment QA and in-vivo verification into the comprehensive RadCalc solution. The RadCalc suite of widely deployed tools in quality assurance (QA) provides medical physicists and dosimetrists with fully automated and independent dosimetric verification of their radiotherapy treatment planning systems (TPS).
We point out that RadCalc’s EPID dosimetry functionalities are protected by the following patents: US Patent 8,351,572 (Jan. 8, 2013), US Patent 8,605,857 (Dec. 10, 2013), and US Patent 10,994,155 (May 4, 2021).
Customer-driven innovation and ongoing improvement continue to be the main drivers for RadCalc QA software development. For more information and to book your personal product demo visit now.